Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus PCV versus radiotherapy plus temozolomide for newly diagnosed 1p/19q-codeleted IDH-mutant glioma
ACTRN12620000402943Phase 3Withdrawn
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of temozolomide, procarbazine, lomustine and vincristine in glioma, anaplastic glioma and low-grade glioma (LGG) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Progression-free survival. Planned start Oct 2022; status: withdrawn.
02
Drugs
temozolomideprocarbazinelomustinevincristine
03
Conditions
gliomaanaplastic gliomalow-grade glioma (LGG)
Beyond the preview
Go deeper on ACTRN12620000402943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000402943.